Table 3 Percentage of patients with no draining fistulas at weeks 26 and 56 for all patients with fistulas at baseline (n  =  117) stratified by baseline concomitant therapies
SubgroupNo draining fistulas*
Week 26 % of patientsWeek 56 % of patients
No baseline immunosuppressant use
    Placebo (n  =  21)1919
    Both adalimumab groups (n  =  39)33 (p = 0.369)36 (p = 0.241)
Baseline immunosuppressant use
    Placebo (n  =  26)88
    Both adalimumab groups (n  =  31)26 (p = 0.092)29 (p = 0.051)
No baseline CD-related antibiotic use
    Placebo (n  =  28)1414
    Both adalimumab groups (n  =  44)32 (p = 0.162)36 (p = 0.059)
Baseline CD-related antibiotic use
    Placebo (n  =  19)1111
    Both adalimumab groups (n  =  26)27 (p = 0.264)27 (p = 0.264)
  • *Patients who had no draining fistulas at the last two post-baseline evaluations in the double-blind period on or before the week 26 or week 56 visits were classified as no; otherwise, patients were classified as yes. p Values from χ2 tests comparing both adalimumab groups combined versus placebo. CD, Crohn’s disease.